Download presentation
Presentation is loading. Please wait.
1
Bringing your projects to a higher level.
Add the company between the green lines. You can just type their name if they don’t have a website. Open by Bringing your projects to a higher level.
2
Agenda Introductions of Cato Team Company Profile Today’s Presentation
3
Cato Research Team Andrée Lefebvre, B.Sc. RAC
Director, Regulatory Affairs & Assistant Managing Director Cato Research Canada Christine Warrington Global Strategic Sales and Marketing Headquarter Office Durham, NC Now that we have had a opportunity to formally introduce ourselves, let’s talk a look specifically at your project and the opportunities that exist between our two organizations.
4
Company Profile We are a full-service contract research and development organization with global resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the drug development process in order to bring new drugs, biologics, and medical devices to the people who need them. Established in 1988, Cato research has established themselves as a full service integrated drug development company that offers innovative and creative regulatory strategies as well as all phases of clinical development in both US and International Clinical trials. The Cato Family is comprised of 320 employees worldwide that have provided our high caliber customized services throughout the industry. Our highly qualified project tams of ph.d’s and mds consistently exhibit an adaptable structure within Cato to allow for the flexibility and responsiveness the sponsor needs. Cato Research is a full-service contract research and development organization with international resources dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory approval process in order to bring new drugs, biologics, and medical devices to the people who need them. We are proud of our company and its role in helping sponsors achieve success in creating better health for people everywhere, and we would like to share more information about Cato Research with you.
5
Cato Research Full service financially stable global drug development company headquartered in RTP, NC. Global presence. Founded in year anniversary Over 300 Employees Project teams lead by Ph.Ds and MDs Established Cato Research Drug Fellowship Program Clients include pharmaceutical, biotechnology, venture capital and academia 62 Employees in europe south Africa and Israel 82 professionals in CTO with 8 MD’s on our staff. Cato Reseach was established Cato research was established in 1988 as a full service integrated drug development company that offers innovative and creative regulatory strategies as well as all phases of global clinical drug development . The Cato Family is comprised of over 300 employees worldwide that provide high caliber customized services throughout the industry. Our highly qualified project teams of ph.d’s and mds consistently exhibit an adaptable structure within Cato to allow for the flexibility and responsiveness the sponsor needs. At Cato Research our people are dedicated to helping pharmaceutical and biotechnology companies efficiently and expeditiously navigate the regulatory and drug development approval process in order to bring new drugs, biologics, and medical devices to the people who need them. Of particular interest to the success of our people is the Cato Drug Development Fellowship Program where over 600 applicants have produced some of the best trained individuals working within Cato but also some of our strongest ambassadors in the healthcare community for our organization. We are proud of our company and its role in helping sponsors achieve success in creating better health for people everywhere, and we would like to share very specific examples of our work.
6
Therapeutic Expertise
Oncology Neurology/Psychiatry Cardiology Gastroenterology Dermatology Endocrinology/Metabolic Disorders Infectious Disease Immunology Hematology Ophthalmology Nephrology Pulmonology Rheumatology Vascular Disorders Anesthesiology and Pain Rare Diseases We have successfully conducted to date over 350 trials successfully utilizing our full international capabilities.. We
7
Worldwide Locations Collaborations Poland Romania Russia Ukraine India
Cologne, Germany Riga, Latvia Montreal, Canada Frankfurt, Germany Graz, Austria San Francisco, CA Boston, MA Szeger, Hungary Washington, MD San Diego, CA Zagreb, Croatia Durham, NC Tel-Aviv, Israel Collaborations Poland Romania Russia Ukraine India Johannesburg, South Africa 7
8
Full Service Development Services
Clinical Trial Services - Phases 1 to 4 Pharmacovigilance Medical Monitoring Data Management Biostatistics Regulatory Quality Assurance Chemistry, Manufacturing, and Controls (CMC) Nonclinical Strategic Consulting From early development through late-phase trials, CATO offers the entire range of integrated product development services you need. No matter where your point of entry in to our resources, CATO will craft a customized program providing seamless access to our full range of development services to meet your specific needs.
9
Quality Assurance Best Practices in a Good Laboratory Practice Environment
10
First, a few words from the wise…
The basic concepts underlying quality systems are quite simple: Say what you do, do what you say, prove it and improve it Janet Woodcook, M.D. Director, Center for Drug Evaluation and Research FDA
11
Why do we need GLP? In the 1950's, 1960's and 1970's, Industrial Bio-Test Laboratories (IBT) performed about 35-40% of all U.S. toxicology testing Of 867 audits of IBT performed by the FDA under the 1962 law, 618 studies were invalid due to numerous discrepancies between the study conduct and data FDA sued and the courts found four IBT managers guilty of fraud As a result of the IBT incident, the FDA decided to regulate laboratory testing In 1976, the FDA GLP guidelines were proposed; they were finalized in 1978 and became effective in 1979
12
The goal is to demonstrate SAFETY of test article before use in humans
Good Laboratory Practice for Nonclinical Laboratory Studies Title 21 Code of Federal Regulations Part 58 The goal is to demonstrate SAFETY of test article before use in humans Do controlled, well-documented laboratory studies Use prospective and approved protocols Document testing methods and findings Provide Quality Assurance review
13
Organization of GLPs GLP Subpart A –– GENERAL PROVISIONS
GLP Subpart B –– ORGANIZATION AND PERSONNEL GLP Subpart C –– FACILITIES GLP Subpart D –– EQUIPMENT GLP Subpart E –– TESTING FACILITIES OPERATION GLP Subpart F –– TEST AND CONTROL ARTICLES GLP Subpart G –– PROTOCOL FOR AND CONDUCT OF STUDY GLP Subparts H-I –– [RESERVED] GLP Subpart J –– RECORDS AND REPORTS GLP Subpart K –– DISQUALIFICATION OF TESTING FACILITIES
14
The 10 Commandments of GLP
Thou shalt appoint study directors and quality assurance Thou shalt be competent, as a result of education, training and experience Honor thy protocol and thy SOPs Thou shalt conduct studies in adequate and clean facilities Thou shalt identify test and control articles and document their use
15
The 10 Commandments of GLP
6. Thou shalt maintain and calibrate equipment according to a specified schedule 7. Thou shalt document and correct all deviations 8. Thou shalt not commit fraud; all thy work thou shalt note, sign and date 9. Thou shalt have archives 10.Thou shalt not turn your back on the FDA
16
A Few Definitions Nonclinical laboratory study
in vivo or in vitro experiments in which test articles are studied prospectively in test systems under laboratory conditions to determine their safety NOT studies utilizing human subjects, clinical studies, field trials in animals, basic exploratory studies for utility, for determining physical or chemical characteristics of a test article
17
A Few Definitions (cont.)
4 important parts of a GLP study Sponsor Management Study Director (SD) Quality Assurance Unit (QAU)
18
A Few Definitions (cont.)
Sponsor A person who initiates and supports a study with financial or other resources A person who submits a nonclinical study to FDA A testing facility, if it both initiates and actually conducts the study
19
A Few Definitions (cont.)
Management Designates a study director before the study starts Replaces the study director promptly if necessary during the study Assures that there is a quality assurance unit Assures that test and control articles or mixtures are tested for identity, strength, purity, stability, and uniformity
20
A Few Definitions (cont.)
Management (continued) Assures that personnel, resources, facilities, equipment, materials, and methodologies are available as scheduled Assures that personnel clearly understand the functions they are to perform Assures that any deviations from these regulations reported by the quality assurance unit are: communicated to the study director and corrective actions are taken and documented
21
A Few Definitions (cont.)
Study Director Scientist of appropriate education, training and experience Responsible for overall technical conduct of a nonclinical laboratory study and for the interpretation, analysis, documentation and reporting of results Assures that all study records are archived at the end of the study
22
A Few Definitions (cont.)
Quality Assurance Unit any person or organizational element, designated by management to perform the duties relating to QA of nonclinical laboratory studies
23
§58.15 Inspection of a testing facility
A testing facility SHALL permit FDA to inspect the facility and to inspect (and copy) all records and specimens Except quality assurance unit records of findings, or corrective actions recommended and taken FDA will not consider a study for a marketing permit if the testing facility refuses to permit inspection and the applicant still must submit the results of the study to FDA!
24
§58.35 Quality Assurance Unit
Duties QAU monitors each study to assure management that all systems are in conformance with GLP regulations QAU shall be entirely independent of personnel conducting a particular study
25
§58.35 Quality Assurance Unit (cont.)
Duties The quality assurance unit shall: Maintain a master schedule sheet of all studies, indexed by test article and listing these elements: test system, nature of study, study initiation date, current status, sponsor identity, and name of the study director
26
§58.35 Quality Assurance Unit (cont.)
Duties Maintain copies of all GLP protocols Inspect each nonclinical laboratory study at adequate intervals; maintain written signed records of periodic inspections Bring to the attention of the study director and management immediately any problems found during an inspection that may affect study integrity
27
§58.35 Quality Assurance Unit (cont.)
Duties Periodically submit to management and to the study director written status reports on each study, noting problems and corrective actions taken Determine that no deviations from approved protocols or standard operating procedures were made without authorization and documentation
28
§58.35 Quality Assurance Unit (cont.)
Duties Review the final study report to assure accuracy in description of methods and Standard Operating Procedures, and that results accurately reflect the raw data of the study Prepare and sign a statement specifying dates of inspections and when findings were reported to management and study director
29
The QAU SOPs (and related)
Topics: GLP Training QA training within the GLP environment Structure of the QAU, e.g. Inspection group, archiving group, validation group QA Reporting Systems, e.g. To respond to QA findings To report to management (including trend analysis)
30
The QAU SOPs (and related)
Topics (continued): Good documentation practices “Inspection” of computer systems QA Master Schedule Archiving procedures (including off site archiving) Disaster recovery plan Data Audit
31
Good Documentation Practice
Documentation should permit the complete reconstruction of a study Record data directly, promptly and legibly in indelible ink (never pencil) Initial and date all observations and any resulting changes, but do not obscure original data Initial and date only work you’ve performed Do not document selectively or in advance of performing the activity
32
Good Documentation Practice
Do not use white-out correction fluid or tape Do not use ditto marks as raw data Copy all heat sensitive paper and stamp “exact copy” Explain why any raw data not used was not used Verify critical calculations using a second person and document this Notebook pages requiring a second signature shall be completed with that signature
33
Good Documentation Practice
Properly head all pages, tables, columns; identify units Describe Statistical & Calculation Procedures used Sign, Date, and File automated printouts (e.g., QC forms) Retain all Raw Data (original records) in the Study File Do not document by exception. Use positive documentation, even if only a check mark.
34
Good Documentation Practice
Documentation must allow another person to be able to accurately reconstruct what you have done Keep all original observations including those observations recorded directly into a computer Sign and date all computer printouts Never back-date anything Follow SOPs and Protocol
35
Good Documentation Practice
Document all deviations with accompanying explanations Indicate in the record all applicable units and equipment used
36
Raw Data Correction All changes to raw data must be made without obscuring the original entry All changes must be initialed and dated by the person making the change, accompanied by an explanation for the change
37
Abbreviations for Reasons
Notation Meaning Definition EE Erroneous Entry Entry of a wrong number or incorrect word SP Spelling Error Entered word is misspelled RD Repeated Data Data are already correctly entered elsewhere MC Miscalculation Number shown is the result of a miscalculation NL Not Legible Entry is illegible or has been overwritten OE-OK Original Entry OK Ignore single line cross-off STET
38
Now, you have selected a CRO…
39
The due diligence starts…
40
Reference: Compliance Program Guidance for FDA Staff
BIMO – Bioresearch Monitoring Good Laboratory Practice (Nonclinical Laboratories) – FDA version A Good Laboratory Practice Program (Nonclinical Laboratories) – EPA Data Audit Inspection
41
Bottom Line… Good Laboratory Practice (Nonclinical Laboratories) is FDA’s instruction manual for its inspectors’ use when they “audit” your GLP facility or study(ies) Be pro-active, and make sure you know what they’ll want to see
42
INSPECTIONAL General Instructions
Determine the current state of GLP compliance by evaluating the laboratory facilities, operations, and study performance Organization Chart - If the facility maintains an organization chart, obtain a current version of the chart for use during your inspection
43
INSPECTIONAL General Instructions (cont.)
Facility Floor-plan – Obtain a diagram of the facility Identify any areas that are not used for GLP activities Use the floor plan during the inspection to ensure that it is really up-to-date
44
INSPECTIONAL General Instructions (cont.)
Master Schedule Sheet Obtain a copy of the firm's master schedule sheet Determine who decides if a study is a GLP study FDA 483’s Obtain a copy and review findings
45
Areas of Expertise of the Facility
Testing facilities may conduct one or more types of GLP studies. Physical-chemical testing Toxicity studies Mutagenicity studies Tissue residue depletion studies Analytical and clinical chemistry testing Other studies (specify)
46
SOP Evaluation Review the SOP index and representative samples of SOPs to ensure coverage of all of the areas identified in GLPs Verify that only current SOPs are available at the personnel workstations Review key SOPs in detail and check for proper authorization signatures and dates, and general adequacy with respect to the content (i.e., SOPs are clear, complete, and can be followed by a trained individual)
47
SOP Evaluation (cont.) Verify that changes to SOPs are properly authorized and dated and that a historical file of SOPs is maintained Ensure that there are procedures for familiarizing employees with SOPs Determine that there are SOPs to ensure the quality and integrity of data, including input (data checking and verification), output (data control), and an audit trail covering all data changes
48
SOP Evaluation (cont.) Verify that a historical file of outdated or modified computer programs is maintained. If the firm does not maintain old programs in digital form, ensure that a hard copy of all programs has been made and stored. Verify that SOPs are periodically reviewed for current applicability and that they are representative of the actual procedures in use Review selected SOPs and observe employees performing the operation to evaluate SOP adherence and familiarity
49
If the firm has computerized operations, determine…
Who was involved in the design, development, and validation of the computer system? Who is responsible for the operation of the computer system, including inputs, processing, and output of data? Determine whether computer system personnel have training commensurate with their responsibilities, including professional training and training in GLPs.
50
If the firm has computerized operations, also determine…
Whether some computer system personnel are contractors who are present on-site full-time, or nearly full-time Include these contractors as though they were employees of the firm Specific inquiry may be needed to identify these contractors, as they may not appear on organization charts Interview and observe personnel using the computerized systems to assess their training and performance of assigned duties
51
Equipment Computers For computer systems, assess that the following procedures exist and are documented: Validation study, including validation plan and documentation of the plan's completion Maintenance of equipment, including storage capacity and back-up procedures Control measures over changes made to the computer system, which include the evaluation of the change, necessary test design, test data, and final acceptance of the change
52
Equipment Computers (cont.)
Evaluation of test data to assure accurate transmission and proper handling when analytical equipment is directly interfaced to the computer Procedures for emergency back-up (e.g., battery system and data forms for recording data in case of computer failure or power outage)
53
Storage and Retrieval of Records
Determine how and where computer data and backup copies are stored, that records are indexed in a way to allow access to data stored on electronic media, and that environmental conditions minimize deterioration
54
Storage of Computer Records
Determine to what electronic media such as tape cassettes or ultra high capacity portable discs the test facility has the capacity of copying records in electronic form Report names and identifying numbers of both copying equipment type and electronic medium type to enable agency personnel to bring electronic media to future inspections for collecting exhibits
55
Assess the procedures by which the study director:
Is assigned and replaced Assures the protocol and any amendments have been properly approved and are followed Assures that all data are accurately recorded and verified Assures that data are collected according to the protocol and SOPs
56
Assess the procedures by which the study director also:
Documents unforeseen circumstances that may affect the quality and integrity of the study and implements corrective action Assures that study personnel are familiar with and adhere to the study protocol and SOPs Assures that study data are transferred to the archives at the close of the study
57
QAU Operations Ratio QA employees to all employees (5 to 8%)
Review and verify QAU SOPs to assure that they cover all methods and procedures for carrying out the required QAU functions, and confirm that they are being followed: Maintenance of a master schedule sheet Maintenance of copies of all protocols and amendments Scheduling of its in-process inspections and audits
58
QAU Operations (cont.) Inspection of each nonclinical laboratory study at intervals adequate to assure the integrity of the study, and maintenance of records of each inspection Immediately notify the SD and management of problems likely to affect the INTEGRITY of the study Submission of periodic status reports on each study to the SD and management
59
QAU Operations (cont.) Review of the final study report
Preparation of a statement to be included in the final report that specifies the dates inspections were made and findings reported to management and to the SD Inspection of computer operations Training
60
More scrutiny of QAU Verify that, for any given study, the QAU is entirely separate from and independent of the personnel engaged in the conduct and direction of that study Evaluate the time QAU personnel spend in performing in-process inspection and final report audits Determine if the time spent is sufficient to detect problems in critical study phases and if there are adequate personnel to perform the required functions
61
Facilities Document any conditions that would lead to contamination of test articles or to unusual stress of test systems Determine that computerized operations and archived computer data are housed under appropriate environmental conditions (e.g., protected from heat, water, and electromagnetic forces)
62
Equipment (other than computers)
For representative pieces of equipment check the availability of the following: SOPs and/or operating manuals Maintenance schedule and log Standardization/calibration procedure, schedule, and log Standards used for calibration and standardization
63
Testing Facilities Operations
Determine if the testing facility has established and follows written SOPs necessary to carry out study operations in a manner designed to ensure the quality and integrity of the data (including method validation) Determine if the testing facility has appropriate controlled storage for study samples Determine if the testing facility maintains and calibrates instrumentation as per SOPs
64
Animal Care Purpose: To assess whether animal care and housing are adequate to minimize stress and uncontrolled influences that could alter the response of test system to the test article Inspect typical animal room(s) that will be housing your study
65
Animal Care (cont.) Review pest-control procedures and documentation of the chemicals used. Identify individuals responsible for the program. When a contractor provides the pest control, determine if someone from the laboratory accompanies the exterminator at all times. Determine whether the facility has an Institutional Animal Care and Use Committee (IACUC). Obtain and submit a copy of the Committee's SOPs and most recent committee minutes to verify committee operation.
66
Test and Control Articles
Characterization and Stability of Test Articles - The responsibility for carrying out appropriate characterization and stability testing may be assumed by the facility performing the study or by your company If you intend to perform the test article characterization and stability testing, verify that the test facility has the procedure in place to document that this testing will have been conducted according to GLP (or GMP)
67
Archiving Determine the number of archive locations – waterproof? Fireproof? Determine who is the individual assigned as archivist Verify method of indexing and the time period when documents/slides/computer data are archived after completion of the study
68
Your audit report Classify your findings
Critical, major, minor or observations Provide a compliance assessment statement Summarize your audit and request a response within 30 days
69
Remembering an FDA Inspection…
70
A Big… Thank you
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.